Celsion Corporation (CLSN)

[sdtrond]

yes, LTG, it certainly will be discussed, and often...

IMO, it will be ad nauseam.

There will be hundreds of posts that disagree violently on whether we should assign a PE multiplier of 20 or 25. Or maybe a xSales of 5? Maybe 7?

But IMO for a biotech that has one candidate for approval, with segmented geographical availability, and EXTREMELY lumpy sales for years out, and LOTS of costs coming up... trying to nail down a SP target by using a single multiple is just wasting lots of bandwidth.

IMO, by the way, means "in my opinion" and that is ALL this post is... my opinion.

Pricing, BTW, has only ever been addressed by MT by saying it's too early to speak of pricing. Bios will hardly ever talk pricing before the drug is actually approved. We can only talk ranges, and even that is probably going to be strongly influenced by the HEAT data. 12v16 will be much different that 13v30, for example.